The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | What leads to shorter progression-free survival in CLL patients?
Clare Sun, MD from the National Heart, Lung, and Blood Institute, Bethesda, MD provides an overview on the progression of ibrutinib treatment in chronic lymphocytic leukemia patients with somatic mutations at the International Workshop for Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY. Dr Sun has focussed on patients on ibrutinib, looking specifically at mutations in the B-cell receptor and NF-kB pathways which can predict clinical outcomes in patients. Shorter progression-free survival (PFS) is thought to be due to greater genomic instability which is dependent on the quantity of mutations. Dr Sun’s data represents the preliminary stage of her study of patients on ibrutinib. Her hope is to follow patients over a longer period to see if mutations change over time, and to determine which patients have shorter PFS requiring alternative therapies.
